Breast cancer remains among the leading causes of cancer-related death worldwide. As research, testing and treatment strategies continue to evolve, clinicians must keep abreast of the latest data on molecular mechanisms, emerging therapies, current standards of care, and new strategies for treatment.

Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European health care providers completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Bethesda, Maryland, USA. Please retain your certificate as proof of completion.

These activities offer credit for oncologists, hematologists, oncology nurses, oncology pharmacists, nurse practitioners, pathologists, and surgeons.

Real-World Evidence: Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer

 

Participate Now

Participate in this free CME Snack to hear Dr. Martine Piccart discuss randomized, controlled trials, real-world data, and real-world evidence, focusing on the current real-world evidence in the field of cyclin-dependent kinase (CDK) 4/6 inhibitors in metastatic breast cancer. Earn CME/CE credit in just 20 minutes!

Case Challenge: Incorporate Real-World Evidence in the Management of Hormone Receptor-Positive Metastatic Breast Cancer

 

Participate Now

In this CME Outfitters BriefCase webcast, expert faculty discuss the challenges and nuances of a case scenario as well as practical strategies for incorporating RWE into daily clinical practice in MBC.

Whiteboard Animation: Real-World Evidence in Metastatic Breast Cancer

In oncology, real-world evidence, or RWE, refers to evidence derived from the use and analysis of real-world data, or RWD, which are data obtained outside the context of randomized controlled trials, or RCTs. View this animation to learn more about RWE in Metastatic Breast Cancer.